Circulating Glutamine and Alzheimer's Disease: A Mendelian Randomization Study.
Charleen D AdamsPublished in: Clinical interventions in aging (2020)
These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer's disease.